<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337360</url>
  </required_header>
  <id_info>
    <org_study_id>NL61414.091.17</org_study_id>
    <secondary_id>NTR6551</secondary_id>
    <nct_id>NCT03337360</nct_id>
  </id_info>
  <brief_title>The Impact of a Nutritional Supplement (Impryl®) on Male Fertility</brief_title>
  <acronym>SUMMER</acronym>
  <official_title>The Impact of a Nutritional Supplement (Impryl®) on Male Fertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Goodlife Fertility B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infertility is a worldwide problem and about 10%-15% of all couples will be affected by the
      inability to have children. In approximately 50% of infertile couples a male factor is
      involved. Male infertility is of multifactorial origin. In the past decade, the role of
      oxidative stress on sperm has been researched thoroughly and found to be the problem in 30%
      to 80% of male infertility cases.

      Impryl® is a nutritional supplement mainly consisting of vitamin B, which works on the
      metabolic system by activating the one carbon cycle and recycling of homocysteine without the
      use of any direct strong antioxidants.

      In this study the investigators want to determine the effectiveness of nutritional supplement
      Impryl® in men of infertile couples on ongoing pregnancy rate, with or without assisted
      reproduction technology (ART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Infertility is a worldwide problem and about 10%-15% of all couples will be
      affected by the inability to have children. In approximately 50% of infertile couples a male
      factor is involved. In the past decade, the role of oxidative stress on sperm has been
      researched thoroughly and found to be the problem in 30% to 80% of male infertility cases.
      Impryl® is a nutritional supplement which works on the metabolic system and regulation of
      oxidative stress by activating the 1-Carbon cycle and therefore recycling of homocysteine.

      Objective: To determine the effectiveness of nutritional supplement Impryl® in men of
      infertile couples on ongoing pregnancy rate, with or without assisted reproduction technology
      (ART).

      Study design: Multicentre, randomised double blind placebo controlled clinical
      trial/superiority study.

      Study population: All participants in this study are male adults, age 18-50 years, part of a
      couple that is diagnosed with infertility, regardless the outcome of semen analysis. The
      couple will either start or is already started with fertility treatment, i.e. expectative
      management (EM, duration 6 months), intra-uterine insemination (IUI) with or without ovarian
      stimulation (mild ovarian hyperstimulation (MOH) or ovulation induction (OI)), either in
      vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment.

      Intervention: Impryl® or placebo, with identical appearance one tablet each day for a total
      duration of maximal 6 months. Intervention has to be consumed for at least 3 consecutive
      months before using semen for IVF or ICSI. In case of expectative management or IUI, patients
      can start directly with fertility treatment and/or to conceive.

      Main study parameters/endpoints: The primary outcome is the number of ongoing pregnancies
      confirmed by ultrasound at ≥ 10-12 weeks. Secondary outcomes are change in semen parameters
      between baseline and 3 months intervention in IUI/IVF/ICSI group, based on (pre-wash) total
      motile sperm count (TMSC), leading to a change in treatment category Furthermore the
      occurrence of pregnancy, time to pregnancy, embryo fertilization rate in IVF/ICSI,
      embryo-utilization rate in IVF/ICSI, number of miscarriages and live birth rate are
      documented within the study period. The occurrence of adverse events will be reported.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, randomised double blind placebo controlled clinical trial/superiority study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>15 months</time_frame>
    <description>Ongoing pregnancy ≥10-12 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall pregnancy rate</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pregnancy 1 - start intervention</measure>
    <time_frame>15 months</time_frame>
    <description>The time between start of intervention and reaching ongoing pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pregnancy 1 - start fertility treatment</measure>
    <time_frame>15 months</time_frame>
    <description>The time between start of fertility treatment and reaching ongoing pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in semen parameters leading to change in treatment category</measure>
    <time_frame>15 months</time_frame>
    <description>Between baseline and 3 months intervention, based on pre-wash total motile sperm count (TMSC) from the subpopulation from Radboudumc and sites that deliver a pre-wash TMSC before IUI/IVF/ICSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of miscarriages</measure>
    <time_frame>15 months</time_frame>
    <description>Defined as a non-vital intra-uterine pregnancy before 16 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>15 months</time_frame>
    <description>Live birth rate defined as beyond 24 weeks of gestation, the birth of a living child.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>15 months</time_frame>
    <description>gastro-intestinal problems such as reflux, obstipation, diarrhea, nausea or vomiting, furthermore loss of appetite, headache, dizziness, pruritus or skin rash.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo fertilization rate</measure>
    <time_frame>15 months</time_frame>
    <description>Relative improvement. Fertilization rate is the percentage of oocytes with &gt;=2 PN after insemination (IVF) of injection (ICSI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo-utilization rate</measure>
    <time_frame>15 months</time_frame>
    <description>Relative improvement of the embryo-utilization rate (EUR), defined as the number of high quality embryos obtained, embryo's used at transfer plus the number of embryos frozen, divided by the number of zygotes obtained in a cycle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Male Subfertility</condition>
  <arm_group>
    <arm_group_label>Impryl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One tablet daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Impryl</intervention_name>
    <description>Food supplement with betaine, cystine, zinc, niacin, folic acid (di5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)</description>
    <arm_group_label>Impryl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive ingredients, placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Couples with failure to conceive for at least 12 months and starting with EM or Couples
        starting with 1stcycle of IUI (with/without ovarian stimulation) or Couples starting with
        1st/ 2nd/3rd cycle of IVF/ICSI

        Furthermore:

          -  Male with age 18-50 years

          -  Female partner with age 18-43 years

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Planned or performed diagnostic testicular biopsy (TESE) or percutaneous epididymal
             sperm aspiration (PESA)

          -  Use of donor-, cryopreserved- or electro-ejaculated semen

          -  Ovulation induction (OI) without IUI

          -  IVF for an absolute tubal factor

          -  Embryo-transfers after cryopreservation

          -  Embryo-transfer after pre-implantation genetic diagnosis

          -  Known genetic abnormalities related to infertility

          -  Known urological abnormality such as a varicocele or bilateral cryptorchism

          -  Use of other vitamin supplements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathrin Fleischer, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gynecologist, head of department of Fertility Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didi Braat, Prof MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologist, head of department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roos Smits, MD</last_name>
    <phone>+31651751244</phone>
    <email>roos.smits@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathrin Fleischer, MD PhD</last_name>
    <email>kathrin.fleischer@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5200ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Peter de Bruin, MD PhD</last_name>
      <email>j.d.bruin@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>Jan Peter de Bruin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maaike Traas, MD PhD</last_name>
      <email>m.traas@gelre.nl</email>
    </contact>
    <investigator>
      <last_name>Maaike Traas, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <zip>6815AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annemiek Nap, MD PhD</last_name>
      <email>ANap@rijnstate.nl</email>
    </contact>
    <investigator>
      <last_name>Annemiek Nap, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasziekenhuis Pantein</name>
      <address>
        <city>Boxmeer</city>
        <zip>5835DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther Haagen, MD</last_name>
      <email>e.haagen@pantein.nl</email>
    </contact>
    <investigator>
      <last_name>Esther Haagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slingeland Ziekenhuis</name>
      <address>
        <city>Doetinchem</city>
        <zip>7002BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rogier Donker, MD PhD</last_name>
      <email>R.Donker@slingeland.nl</email>
    </contact>
    <investigator>
      <last_name>Rogier Donker, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nij Geertgen</name>
      <address>
        <city>Elsendorp</city>
        <zip>5424SM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marieke Schoonenberg, MD</last_name>
      <email>marieke.schoonenberg@nijgeertgen.nl</email>
    </contact>
    <contact_backup>
      <last_name>Martine Nijs, MSc PhD</last_name>
      <email>Martine.Nijs@nijgeertgen.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marieke Schoonenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ron van Golde, MD PhD</last_name>
      <email>ron.van.golde@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Ron van Golde, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roos Smits, MSc</last_name>
      <email>roos.smits@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Fleischer, Dr</last_name>
      <email>kathrin.fleischer@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Roos Smits, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathrin Fleischer, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5022GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Smeenk, MD PhD</last_name>
      <email>j.smeenk@etz.nl</email>
    </contact>
    <investigator>
      <last_name>Jesper Smeenk, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bernhoven Ziekenhuis</name>
      <address>
        <city>Uden</city>
        <zip>5400AS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcel Hoekstra, MD PhD</last_name>
      <email>m.hoekstra@bernhoven.nl</email>
    </contact>
    <investigator>
      <last_name>Marcel Hoekstra, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Máxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Maas, MD PhD</last_name>
      <email>Jacques.Maas@mmc.nl</email>
    </contact>
    <investigator>
      <last_name>Jacques Maas, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://impryl.com/</url>
    <description>Website Impryl</description>
  </link>
  <reference>
    <citation>Iwasaki A, Gagnon C. Formation of reactive oxygen species in spermatozoa of infertile patients. Fertil Steril. 1992 Feb;57(2):409-16.</citation>
    <PMID>1735495</PMID>
  </reference>
  <reference>
    <citation>Zini A, de Lamirande E, Gagnon C. Reactive oxygen species in semen of infertile patients: levels of superoxide dismutase- and catalase-like activities in seminal plasma and spermatozoa. Int J Androl. 1993 Jun;16(3):183-8.</citation>
    <PMID>8359932</PMID>
  </reference>
  <reference>
    <citation>Shekarriz M, Thomas AJ Jr, Agarwal A. Incidence and level of seminal reactive oxygen species in normal men. Urology. 1995 Jan;45(1):103-7.</citation>
    <PMID>7817460</PMID>
  </reference>
  <reference>
    <citation>Agarwal A, Prabakaran S, Allamaneni S. What an andrologist/urologist should know about free radicals and why. Urology. 2006 Jan;67(1):2-8. Review.</citation>
    <PMID>16413322</PMID>
  </reference>
  <reference>
    <citation>Tremellen K. Oxidative stress and male infertility--a clinical perspective. Hum Reprod Update. 2008 May-Jun;14(3):243-58. doi: 10.1093/humupd/dmn004. Epub 2008 Feb 14. Review.</citation>
    <PMID>18281241</PMID>
  </reference>
  <reference>
    <citation>Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2014;(12):CD007411. doi: 10.1002/14651858.CD007411.pub3. Epub 2014 Dec 15. Review.</citation>
    <PMID>25504418</PMID>
  </reference>
  <reference>
    <citation>Dattilo M, Cornet D, Amar E, Cohen M, Menezo Y. The importance of the one carbon cycle nutritional support in human male fertility: a preliminary clinical report. Reprod Biol Endocrinol. 2014 Jul 29;12:71. doi: 10.1186/1477-7827-12-71.</citation>
    <PMID>25073983</PMID>
  </reference>
  <reference>
    <citation>Dattilo M, Giuseppe D, Ettore C, Ménézo Y. Improvement of gamete quality by stimulating and feeding the endogenous antioxidant system: mechanisms, clinical results, insights on gene-environment interactions and the role of diet. J Assist Reprod Genet. 2016 Dec;33(12):1633-1648. Epub 2016 Jul 16. Review. Erratum in: J Assist Reprod Genet. 2017 Jan;34(1):155.</citation>
    <PMID>27423667</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fertility</keyword>
  <keyword>male subfertility</keyword>
  <keyword>foodsupplement</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

